ATA Action Comments to the FDA Regarding Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products

ATA Action submitted comments in response to the Food and Drug Administration’s (FDA) request for information regarding the advancement of digital health technologies (DHTs) in clinical investigations (Docket No. FDA-2026-N-2476 — Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products).